Table of Content

1. Blood Products
1.1 Definition
1.2 Classification
1.3 Recombinant Blood Products
1.4 Industry Chain
1.5 Features


2. China Blood Product Market
2.1 Policies
2.2 Status Quo
2.3 Market Structure
2.4 Supply and Demand
2.4.1 Supply
2.4.2 Demand
2.5 Market Size
2.6 Competitive Pattern


3. China Blood Product Market Segments
3.1 Human Albumin
3.1.1 Status Quo
3.1.2 Bid Price
3.1.3 Market Structure
3.1.4 Competitive Pattern
3.1.5 Prospects
3.2 Human Immunoglobulin (pH4) for Intravenous Injection
3.2.1 Status Quo
3.2.2 Bid Price
3.2.3 Competitive Pattern
3.2.4 Prospects
3.3 Coagulation Factor VIII
3.3.1 Status Quo
3.3.2 Bid Price
3.3.3 Competitive Pattern
3.3.4 Prospects
3.4 Human Hepatitis B Immunoglobulin
3.4.1 Status Quo
3.4.2 Bid Price
3.4.3 Competitive Pattern
3.5 Human Immunoglobulin
3.5.1 Status Quo
3.5.2 Bid Price
3.5.3 Competitive Pattern
3.6 Human Prothrombin Complex
3.6.1 Status Quo
3.6.2 Bid Price
3.6.3 Competitive Pattern
3.7 Human Tetanus Immunoglobulin
3.7.1 Status Quo
3.7.2 Bid Price
3.7.3 Competitive Pattern
3.8 Human Rabies Immunoglobulin
3.8.1 Status Quo
3.8.2 Bid Price
3.8.3 Competitive Pattern


4. Major Enterprises
4.1 China Biologic Products (CBPO)
4.1.1 Profile
4.1.2 Operation
4.1.3 Revenue Structure
4.1.4 Gross Margin
4.1.5 R&D Investment
4.1.6 Blood Products Business
4.1.7 Guizhou Taibang Biological Products Co., Ltd.
4.1.8 Shandong Taibang Biological Products Co., Ltd.
4.1.9 Xi’an Huitian Blood Products Co., Ltd.
4.2 Hualan Biological Engineering Co., Ltd.
4.2.1 Profile
4.2.2 Operation
4.2.3 Revenue Structure
4.2.4 Gross Margin
4.2.5 R&D Investment
4.2.6 Blood Products Business
4.2.7 Development Strategy
4.3 Shanghai RAAS Blood Products Co., Ltd.
4.3.1 Profile
4.3.2 Operation
4.3.3 Revenue Structure
4.3.4 Gross Margin
4.3.5 R&D Investment
4.3.6 Blood Products Business
4.3.7 Development Strategy
4.4 Beijing Tiantan Biological Products
4.4.1 Profile
4.4.2 Operation
4.4.3 Revenue Structure
4.4.4 Gross Margin
4.4.5 R&D Investment
4.4.6 Blood Products Business
4.4.7 Chengdu Rongsheng
4.4.8 Dynamics
4.5 Guangdong Shuanglin Bio-Pharmacy
4.5.1 Profile
4.5.2 Operation
4.5.3 Gross Margin
4.5.4 R&D Investment
4.5.5 Blood Products Business
4.5.6 Dynamics
4.6 Jiangxi Boya Bio-Pharmaceutical
4.6.1 Profile
4.6.2 Operation
4.6.3 Revenue Structure
4.6.4 Gross Margin
4.6.5 R&D Investment
4.6.6 Blood Products Business
4.6.7 Dynamics
4.7 Weiguang Biological Products
4.7.1 Profile
4.7.2 Operation
4.7.3 Revenue Structure
4.7.4 Gross Margin
4.7.5 R&D Investment
4.7.6 Blood Products Business
4.7.7 Development Strategy
4.8 Beijing Bohui Innovation Technology
4.8.1 Profile
4.8.2 Operation
4.8.3 Revenue Structure
4.8.4 Gross Margin
4.8.5 R&D Investment
4.8.6 Blood Products Business
4.8.7 Development Strategy
4.8.8 Dynamics
4.9 Wuhan ZhongyuanRuide Biological Products Co., Ltd.
4.9.1 Profile
4.9.2 Operation
4.9.3 Blood Products Business
4.10 Sichuan Yuanda Shuyang Pharmaceutical Co., Ltd.
4.10.1 Profile
4.10.2 Blood Products Business
4.10.3 Development Strategy
4.11 Shanxi Kangbao Biological Product Co., Ltd.
4.11.1 Profile
4.11.2 Blood Products Business
4.12 Green Cross China
4.12.1 Profile
4.12.2 Blood Products Business
4.13 Nanyue Biopharming Corporation Ltd.
4.13.1 Profile
4.13.2 Blood Products Business
4.13.3 Development Strategy


5. Summary and Forecast
5.1 Summary
5.2 Development Trends
5.2.1 The Industry Continues to Boom
5.2.2 Industry Integration Speeds Up, Concentration Rises Further
5.2.3 Plasma Collection Volume and Number of Plasma Stations Determine the Status in the Industry
5.2.4 Plasma Collection Volume Increases Progressively
5.2.5 Enterprises Make More Input in R&D of New Products to Sharpen Competitiveness, Comprehensive Utilization of Blood Plasma Gets a Further Rise
5.2.6 Downstream Demand Stimulates the Industry
5.2.7 Healthcare System Reform Deepens, Gradual Perfection of Medical Insurance System Favors the Growth of the Industry
5.2.8 COVID-19 Pandemic Brings Development Opportunities to Domestic Companies



List of Figures


Basic Components of Blood
Plasma Protein Separation Procedure
Classification and Effects of Blood Products
Comparison between Gene Recombinant Blood Products and Traditional Blood Products
Comparison of Recombinant Blood Products in China and Overseas
Blood Product Industry Chain
Time Length of Plasma Collection and Separation Process
Comparison between Blood Product Enterprises and Chemical & Pharmaceutical Enterprises in Operating Costs & Expenses
Production & Sales Cycle of Blood Products
Main Policies on China Blood Product Industry, 1986-2020
Development History of China Blood Product Industry
Comparison between China and the United States in Per Capita Consumption of Main Blood Products
Lot Release Volume of Major Blood Products in China, 2014-2020
Structure of Blood Products in China (by Lot Release Volume), 2020
Plasma Collection Policies in China vs. USA and European Countries
Per Capita Frequency of Plasma Donation and Plasma Collection Volume in China vs. Euro-America
Number of Plasma Collection Stations and YoY Growth in China, 2008-2020
Plasma Station Approval of Major Blood Product Enterprises in China, 2014-2019
Plasma Collection Volume and YoY Growth in China, 2008-2019
Plasma Collection Volume Structure of Major Blood Product Enterprises in China, 2018-2019
Comparison of Blood Products Listed in National Medical Insurance Catalogue, 2017 vs 2009
Plasma Supply and Demand in China, 2015-2025E
Comparison of Cap-lift Prices and Original Highest Retail Prices of Blood Products
Market Size of China Blood Product Industry, 2010-2020
Number of Plasma Stations and Plasma Volume of Major Blood Product Enterprises in China, as of Dec. 2019
Main Products of Major Blood Product Producers in China
Revenue of Major Blood Product Enterprises in China, 2013-2020
Net Income of Major Blood Product Enterprises in China, 2013-2020
Revenue from Blood Products Business of Major Blood Product Enterprises in China, 2013-2020
Market Share of China Blood Product Industry (by Enterprise), 2018
Market Share of China Blood Product Industry (by Enterprise), 2019
Lot Release Volume and YoY Growth of Human Albumin in China, 2010-2020
Average Successful Bid Prices Offered by Major Blood Product Enterprises in China for Human Albumin, 2019
Average Successful Bid Prices for Human Albumin in China, 2017-2020
Proportion of Domestic and Imported Human Albumin in China (by Lot Release Volume), 2007-2020
Lot Release Volume Structure of Human Albumin in China (by Enterprise), 2018
Lot Release Volume Structure of Human Albumin in China (by Enterprise), 2019
Lot Release Volume Structure of Human Albumin in China (by Enterprise), 2020
Major Enterprises’ Deployments in Recombinant Human Albumin in China
Lot Release Volume of Human Immunoglobulin (pH4) for Intravenous Injection in China, 2010-2020
Average Successful Bid Prices Offered by Major Blood Product Enterprises in China for Human Immunoglobulin (pH4) for Intravenous Injection, 2019
Average Successful Bid Prices for Human Immunoglobulin (pH4) for Intravenous Injection in China, 2016-2020
Lot Release Volume Structure of Human Immunoglobulin (pH4) for Intravenous Injection in China (by Enterprise), 2018
Lot Release Volume Structure of Human Immunoglobulin (pH4) for Intravenous Injection in China (by Enterprise), 2019
Lot Release Volume Structure of Human Immunoglobulin (pH4) for Intravenous Injection in China (by Enterprise), 2020
Comparison between China and the United States in Per Capita Consumption of Human Albumin and Human Immunoglobulin (pH4) for Intravenous Injection
Lot Release Volume and YoY Growth of Blood Coagulation Factor VIII in China, 2010-2020
Average Successful Bid Prices Offered by Major Blood Product Enterprises in China for Coagulation Factor VIII, 2019
Lot Release Volume Structure of Blood Coagulation Factor VIII in China (by Enterprise), 2018
Lot Release Volume Structure of Blood Coagulation Factor VIII in China (by Enterprise), 2019
Lot Release Volume Structure of Blood Coagulation Factor VIII in China (by Enterprise), 2020
Comparison between China and the United States in Per Capita Consumption of Coagulation Factor VIII
Coagulation Factor VIII R&D Progress of Major Blood Product Enterprises in China, as of 2019H1
Lot Release Volume and YoY Growth of Human Hepatitis B Immunoglobulin in China, 2010-2020
Average Successful Bid Prices Offered by Major Blood Product Enterprises in China for Human Hepatitis B Immunoglobulin, 2019
Lot Release Volume Structure of Human Hepatitis B Immunoglobulin in China (by Enterprise), 2018
Lot Release Volume Structure of Human Hepatitis B Immunoglobulin in China (by Enterprise), 2019
Lot Release Volume Structure of Human Hepatitis B Immunoglobulin in China (by Enterprise), 2020
Lot Release Volume and YoY Growth of Human Immunoglobulin in China, 2010-2020
Average Successful Bid Prices Offered by Major Blood Product Enterprises in China for Human Immunoglobulin, 2019
Lot Release Volume Structure of Human Immunoglobulin in China (by Enterprise), 2018
Lot Release Volume Structure of Human Immunoglobulin in China (by Enterprise), 2019
Lot Release Volume Structure of Human Immunoglobulin in China (by Enterprise), 2020
Lot Release Volume and YoY Growth of Human Prothrombin Complex in China, 2010-2020
Average Successful Bid Prices Offered by Major Blood Product Enterprises in China for Human Prothrombin Complex, 2019
Lot Release Volume Structure of Human Prothrombin Complex in China (by Enterprise), 2018
Lot Release Volume Structure of Human Prothrombin Complex in China (by Enterprise), 2019
Lot Release Volume Structure of Human Prothrombin Complex in China (by Enterprise), 2020
Lot Release Volume and YoY Growth of Human Tetanus Immunoglobulin in China, 2010-2019
Average Successful Bid Prices Offered by Major Blood Product Enterprises in China for Human Tetanus Immunoglobulin, 2019
Lot Release Volume Structure of Human Tetanus Immunoglobulin in China (by Enterprise), 2018
Lot Release Volume Structure of Human Tetanus Immunoglobulin in China (by Enterprise), 2019
Lot Release Volume Structure of Human Tetanus Immunoglobulin in China (by Enterprise), 2020
Cases, Deaths and Mortality of Rabies in China, 2013-2020
Lot Release Volume and YoY Growth of Human Rabies Immunoglobulin in China, 2010-2020
Average Successful Bid Prices Offered by Major Blood Product Enterprises in China for Human Rabies Immunoglobulin, 2019
Lot Release Volume Structure of Human Rabies Immunoglobulin in China (by Enterprise), 2018
Lot Release Volume Structure of Human Rabies Immunoglobulin in China (by Enterprise), 2019
Lot Release Volume Structure of Human Rabies Immunoglobulin in China (by Enterprise), 2020
Product Line of CBPO
Equity Structure of China Biologic Products Holdings
Revenue and Operating Income of CBPO, 2015-2020
Revenue Breakdown of CBPO (by Product), 2012-2020
Revenue Structure of CBPO (by Product), 2012-2020
Gross Margin of CBPO, 2012-2020
R&D Costs and % of Total Revenue of CBPO, 2012-2020
CBPO’s Products under Research and R&D Process by the end of 2019
Main Products in R&D Pipeline of Beijing TianXinFu Medical Appliance
Lot Release Volume of Blood Products of CBPO, 2016-2020
Main Plasma Collection Stations of Guizhou Taibang Biological Products as of Dec. 2019
Equity Structure of Shandong Taibang Biological Products
Main Plasma Collection Stations of Shandong Taibang Biological Products as of Dec. 2019
Equity Structure of Xi’an Huitian Blood Products
Main Plasma Collection Stations of Xi’an Huitian Blood Products as of Dec. 2019
Lot Release Volume of Blood Products of Xi’an Huitian Blood Products, 2017-2020
Revenue and Net Income of Hualan Biological Engineering, 2013-2020
Revenue Breakdown of Hualan Biological Engineering (by Product), 2013-2020
Revenue Structure of Hualan Biological Engineering (by Product), 2013-2020
Gross Margin of Blood Products of Hualan Biological Engineering (by Product), 2013-2020
R&D Costs and % of Total Revenue of Hualan Biological Engineering, 2013-2020
Category and Specification of Blood Products of Hualan Biological Engineering
Output, Sales Volume and Inventory of Blood Products of Hualan Biological Engineering, 2016-2019
Hualan Biological Engineering’s Revenue from Blood Product Business and % of Total Revenue, 2013-2020
Lot Release Volume of Blood Products of Hualan Biological Engineering, 2015-2020
Revenue and Net Income of Shanghai RAAS Blood Products, 2013-2020
Revenue Breakdown of Shanghai RAAS Blood Products (by Product), 2013-2020
Revenue Structure of Shanghai RAAS Blood Products (by Product), 2013-2020
Revenue Breakdown of Shanghai RAAS Blood Products (by Region), 2013-2020
Revenue Structure of Shanghai RAAS Blood Products (by Region), 2013-2020
Gross Margin of Shanghai RAAS Blood Products (by Product), 2013-2020
Shanghai RAAS Blood Products’ R&D Costs and % of Total Revenue, 2013-2020
Blood Products of Shanghai RAAS Blood Products and Its Subsidiaries
Output, Sales Volume and Inventory of Blood Products of Shanghai RAAS Blood Products, 2016-2019
Revenue and Net Income of Tiantan Biological Products, 2013-2020
Revenue Breakdown of Tiantan Biological Products (by Product), 2013-2020
Revenue Structure of Tiantan Biological Products (by Product), 2013-2020
Gross Margin of Tiantan Biological Products (by Product), 2013-2020
Tiantan Biological Products’ R&D Costs and % of Total Revenue, 2013-2020
Tiantan Biological Products’ R&D Input in Major Drugs and % of Total Revenue, 2019
Progress of Major R&D Projects of Tiantan Biological Products, by the End of 2019
Tiantan Biological Products’ Major Blood Products Subsidiaries and Its Stake in Them
Production and Sales of Main Blood Products of Tiantan Biological Products, 2019
Lot Release Volume of Main Blood Products of Tiantan Biological Products, 2015-2020
Revenue and Net Income of Chengdu Rongsheng Pharmaceutical, 2015-2020
Uses of Funds Tiantan Biological Products Raised by Non-public Offering of A Shares in Oct. 2020
Blood Product Clinical Research Projects of Chengdu Rongsheng Pharmaceutical
Structure of Investments in Blood Product Clinical Research Projects of Chengdu Rongsheng Pharmaceutical
Revenue and Net Income of Shuanglin Bio-Pharmacy, 2013-2020
Gross Margin of Shuanglin Bio-Pharmacy, 2013-2020
Shuanglin Bio-Pharmacy’s R&D Costs and % of Total Revenue, 2013-2020
Revenue and Net Income of Guangdong Shuanglin Bio-Pharmacy, 2014-2019
Production-use Plasma Volume of Guangdong Shuanglin Bio-Pharmacy, 2013-2019
Production, Inventory and Sales of Blood Products of Guangdong Shuanglin Bio-Pharmacy, 2013-2019
Lot Release Volume of Blood Products of Guangdong Shuanglin Bio-Pharmacy, 2015-2020
Revenue and Net Income of Jiangxi Boya Bio-Pharmaceutical, 2013-2020
Revenue Breakdown of Jiangxi Boya Bio-Pharmaceutical (by Business), 2013-2020
Revenue Structure of Jiangxi Boya Bio-Pharmaceutical (by Business), 2013-2020
Revenue from Major Blood Products of Jiangxi Boya Bio-Pharmaceutical, 2015-2020
Revenue Proportion of Major Blood Products of Jiangxi Boya Bio-Pharmaceutical, 2015-2020
Gross Margin of Jiangxi Boya Bio-Pharmaceutical (by Product), 2013-2020
Gross Margin of Main Blood Products of Jiangxi Boya Bio-Pharmaceutical, 2013-2020
Jiangxi Boya Bio-Pharmaceutical’s R&D Costs and % of Total Revenue, 2013-2020
Production and Sales of Blood Products of Jiangxi Boya Bio-Pharmaceutical, 2016-2019
Lot Release Volume of Blood Products of Jiangxi Boya Bio-Pharmaceutical, 2015-2020
Revenue and Net Income of Shenzhen Weiguang Biological Products, 2014-2020
Revenue Breakdown of Shenzhen Weiguang Biological Products (by Product), 2014-2020
Revenue Structure of Shenzhen Weiguang Biological Products (by Product), 2014-2020
Gross Margin of Shenzhen Weiguang Biological Products, 2014-2020
Gross Margin of Main Blood Products of Shenzhen Weiguang Biological Products, 2014-2020
Shenzhen Weiguang Biological Products’ R&D Costs and % of Total Revenue, 2014-2020
Progress of Fundraising Projects of Shenzhen Weiguang Biological Products, as of 2020H1
Plasma Collection Volume of Shenzhen Weiguang Biological Products, 2014-2019
Production and Sales of Blood Products of Shenzhen Weiguang Biological Products, 2016-2019
Financial Data of Main Plasma Collection Subsidiaries of Shenzhen Weiguang Biological Products, 2020H1
Lot Release Volume of Blood Products of Shenzhen Weiguang Biological Products, 2016-2020
Revenue and Net Income of Beijing Bohui Innovation Technology, 2014-2020
Revenue Breakdown of Beijing Bohui Innovation Technology by Product, 2014-2020
Revenue Structure of Beijing Bohui Innovation Technology by Product, 2014-2020
Gross Margin of Beijing Bohui Innovation Technology by Product, 2014-2020
Beijing Bohui Innovation Technology’s R&D Costs and % of Total Revenue, 2014-2020
Beijing Bohui Innovation Technology’s Main Ongoing Projects and Their Registration Progress, 2020H1
Major Blood Products of Beijing Bohui Innovation Technology
Financials of Beijing Bohui Innovation Technology, 2017-2020
Lot Release Volume of Blood Products of Hebei Da’an Pharmaceutical, 2016-2020
Lot Release Volume of Blood Products of Guangdong Weilun Biological Pharmaceutical, 2016-2020
Development Course of Zhongyuan Ruide Biological Products
Financial Data of Zhongyuan Ruide, 2014-2018
Plasma Collection Stations of Wuhan ZhongyuanRuide Biological Products, as of Dec. 2019
Lot Release Volume of Blood Products of Zhongyuan Ruide Biological Products, 2016-2019
Development History of Sichuan Yuanda Shuyang Pharmaceutical
Specification of Blood Products of Sichuan Yuanda Shuyang Pharmaceutical
Lot Release Volume of Blood Products of Sichuan Yuanda Shuyang Pharmaceutical, 2016-2020
Main Plasma Collection Stations of Shanxi Kangbao Biological Product as of Dec. 2019
Lot Release Volume of Blood Products of Shanxi Kangbao Biological Product, 2016-2020
Main Plasma Collection Stations of Green Cross China as of Dec. 2019
Lot Release Volume of Blood Products of Green Cross China, 2016-2020
Main Plasma Collection Stations of Nanyue Biopharming, as of Dec. 2019
Lot Release Volume of Blood Products of Nanyue Biopharming, 2016-2020
Market Size of Blood Products in China, 2018-2026E
M&A Cases of Foreign Blood Product Companies
M&A Cases in China Blood Product Industry, 2008-2020
Plasma Collection Volume of Tiantan Biological Products, 2016-2019
Plasma Collection Volume Structure of Major Companies in China, 2019
Plasma Collection Volume and YoY Change in China, 2019-2026E
R&D Investment of Major Chinese Blood Product Enterprises, 2014-2020
Population Aged above 60 as a Percentage of Total Population in China, 2009-2019